CCR2-based blood test and PET imaging to detect bone marrow fibrosis in myeloproliferative neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project will measure CD34+CCR2+ cells in peripheral blood by flow cytometry and develop a CCR2-targeted PET tracer to image fibrotic bone marrow non-invasively. Work combines preclinical validation and a first-in-human proof-of-concept imaging approach. The goal is a diagnostic algorithm that uses blood and imaging biomarkers to identify fibrotic progression without routine bone marrow biopsy. The approach is intended for use at diagnosis, during follow-up for suspected progression, or when biopsy is contraindicated.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of ET/PV/prePMF/overtPMF according to the WHO 2016 criteria and of SMF according to the IWG-MRT criteria (with histopathological data).
* Age \>= 18 yrs
* ECOG performance status \<=3

Exclusion Criteria:

* Pregnancy/breastfeeding
* Ongoing therapy with immunomodulatory drugs (JAK-inhibitors, interferon).
* For PET imaging, patients should be off any cytoreductive treatment for at least 3 months.
* Antiplatelet agents are allowed

Where it's running

• Dipartimento di Medicina e Chirurgia
  Parma, Italy, Italy Recruiting

Study contacts

• Study coordinator: Elena Masselli, MD, PhD
• Email: elena.masselli@unipr.it
• Phone: +39 0521 906655

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

  This study tests how outcomes differ for patients 16 and older with polycythemia vera, essential thrombocythemia, or myelofibrosis by collecting and analyzing clinical and treatment data.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07863466

• Pacritinib Effectiveness in Real-world Settings

  This real-world study will see how pacritinib works for adults with myelofibrosis by looking back at medical records from several centers.

  Recruiting at 5 sites Swedish Orphan Biovitrum · New Haven, Connecticut and 4 other locations · NCT07774455

• PRT12396 for people with high-risk polycythemia vera or myelofibrosis

  The team will try the oral drug PRT12396 in people with high-risk polycythemia vera or myelofibrosis to find safe doses and look for early signs of benefit.

  Recruiting at 22 sites Phase 1 Prelude Therapeutics Incorporated · Los Angeles, California and 21 other locations · NCT07469891

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Early Tacrolimus Taper After Allogeneic Transplant

  This study tests whether stopping tacrolimus early after an allogeneic stem cell transplant is safe and feasible for people with AML, MDS, MF, CML, CMML, or GVHD risk after transplant.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT07302776

• Axatilimab plus ruxolitinib for people with myelofibrosis or CMML

  This trial tests whether adding axatilimab, an antibody that targets CSF1R, to ruxolitinib can help control disease and symptoms in adults with myelofibrosis or chronic myelomonocytic leukemia (CMML).

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07128381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.